Table 2.
Current available non–anti-TNF Biologics treatments in non-infectious uveitis.
| Therapy | Description | Study type | References |
|---|---|---|---|
| Tocilizumab | Anti-IL-6 humanized antibody | Systematic review | (Lopalco et al., 2017a) |
| Clinical trial | (Papo et al., 2014) | ||
| Systematic review | (Cann et al., 2018) | ||
| Systematic review | (Sharma et al., 2018) | ||
| Retrospective study | (Silpa-Archa et al., 2016) | ||
| Secukinumab | Anti-IL-17A monoclonal antibody | Clinical trial | (Dick et al., 2013) |
| Review | (Sanford and McKeage, 2015) | ||
| Canakinumab | Anti-IL-1β | Case report | (Simonini et al., 2013b) |
| Systematic review | (Simonini et al., 2015) | ||
| Anakinra | IL-1 receptor antagonist | Systematic review | (Simonini et al., 2015) |
| Rituximab | Anti CD20 antibody | Systematic review | (Simonini et al., 2015) |
| Retrospective study | (Miserocchi et al., 2016) | ||
| Clinical trial | (Davatchi et al., 2010) |
IL, interleukin; CD, cluster of differentiation.